3SBio, a China partner of U.S. drug giant Pfizer, has reached agreements to raise approximately $400 million in a share ...

Pfizer's strategy that will help it rebound from recent struggles is in full motion. It says a lot that the company continues ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Holmes’ attack on evidence that led to her conviction comes amid an apparent campaign to obtain a pardon from President ...

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

The company's earnings fell by 21% last quarter.

The weight loss drug market may approach almost $100 billion by the end of the decade.

Most of the dividend increases announced in the last two weeks of November were in the low-to-mid single-digit percentages.

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

To get a sense of who is truly in control of Pfizer Inc. (NYSE:PFE), it is important to understand the ownership structure of ...

Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong ...